- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Parenteral formulations of cangrelor.
Coronary artery disease PCI patient: reduction of thrombotic events
Cangrelor, co-administered with aspirin, is indicated for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
The recommended dose of cangrelor for patients undergoing PCI is 30micrograms/kg intravenous bolus followed immediately by 4micrograms/kg/minute intravenous infusion.
The bolus and infusion should be initiated prior to the procedure and continued for at least two hours or for the duration of the procedure, whichever is longer. At the discretion of the physician, the infusion may be continued for a total duration of four hours.
Additional Dosage Information
Patients should be transitioned to oral P2Y12 therapy for chronic treatment. For transition, a loading dose of oral P2Y12 therapy (clopidogrel, ticagrelor or prasugrel) should be administered immediately following discontinuation of cangrelor infusion. Alternatively, a loading dose of ticagrelor or prasugrel, but not clopidogrel, may be administered up to 30 minutes before the end of the infusion (see specific product literature).
In patients undergoing PCI, standard procedural adjunctive therapy should be implemented.
For intravenous administration.
Children under 18 years
Risk of haemorrhage
Hereditary fructose intolerance
History of cerebrovascular accident
History of transient ischaemic attack
Uncontrolled severe hypertension
Precautions and Warnings
Predisposition to haemorrhage
Renal impairment - creatinine clearance below 30 ml/minute
Presentations with sorbitol unsuitable in hereditary fructose intolerance
Must be diluted before use
Treatment to be administered under the supervision of a specialist
Monitor for unexplained fall in blood pressure or haematocrit
Potential for increased risk of bleeding
Discontinue if haemorrhage occurs
Discontinue if unexplained fall in blood pressure or haematocrit occurs
Cangrelor has a half-life of 3 to 6 minutes. Platelet function is restored within 60 minutes of stopping infusion.
Pregnancy and Lactation
Cangrelor is contraindicated during pregnancy.
Use of cangrelor during pregnancy is contraindicated by the manufacturer. Studies in animals have shown reproductive toxicity. There is limited data on the use of cangrelor in pregnant women. Potential risks are unknown.
Cangrelor is contraindicated during breastfeeding.
The manufacturer makes no recommendation regarding use of cangrelor during breastfeeding. The presence of cangrelor in human breast milk is unknown. Effects on exposed infants are unknown.
Acute renal failure
Decrease in haemoglobin and haematocrit
Discharge (injection site)
Haematoma (injection site)
Increase in creatinine
Reduced platelet count
Reduction in blood count
Skin neoplasm bleeding
Subcutaneous haematoma (injection site)
Urinary tract bleeding
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: July 2019
Summary of Product Characteristics: Kengrexal 50 mg powder for concentrate for solution for injection/infusion. Chiesi Ltd. Revised December 2019.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 11 July 2019
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.